NCT06046937 is a EARLY_PHASE1 clinical trial of Monolaurin in Bacterial Infections, sponsored by Victoriano Luna Medical Center.

Who is sponsoring NCT06046937?

NCT06046937 is sponsored by Victoriano Luna Medical Center.

What drugs are being tested in NCT06046937?

Interventions in NCT06046937: Monolaurin, Mupirocin ointment.

What condition does NCT06046937 study?

NCT06046937 studies Bacterial Infections.

Is NCT06046937 still recruiting?

NCT06046937 is currently completed. Last updated 17 October 2023.

Last reviewed 2023-10-17 · How we verify

NCT06046937

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Monolaurin Ointment Versus Mupirocin Ointment

Completed EARLY_PHASE1 Last updated 17 October 2023

What this trial tests

EARLY_PHASE1 trial testing Monolaurin in Bacterial Infections in 40 participants. Completed in 15 July 2023.

Timeline

1 June 2023

Primary endpoint
30 June 2023

15 July 2023

Quick facts

Lead sponsor	Victoriano Luna Medical Center
Phase	EARLY_PHASE1
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	40
Start date	1 June 2023
Primary completion	30 June 2023
Estimated completion	15 July 2023
Sites	1 location across Philippines

Drugs / interventions tested

Monolaurin
Mupirocin ointment — full drug profile →

Conditions studied

Bacterial Infections — all drugs for Bacterial Infections →

Sponsor

Victoriano Luna Medical Center

Who can join

Adults 5 to 18, any sex, with Bacterial Infections. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Skin infection remains one of the leading causes of pediatric consults especially in developing countries like the Philippines. This common condition has not been considered a significant problem that could cause alarm as public health importance. Furthermore, due to the consideration that skin diseases are benign, not life-threatening, and low priority.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Bacterial Infections

Currently open trials in the same condition.

NCT07017777 — A Study to Evaluate the Immunogenicity and Safety of 13-valent Pneumococcal Conjugate Vaccine (PCV13i) in Healthy Infant · Phase 3 · recruiting
NCT07104162 — A Study to Investigate Safety and Pharmacokinetics of Intravenous Cefiderocol/Xeruborbactam in Participants With Renal I · Phase 1 · recruiting
NCT07207291 — Phase I Study of Single/Multiple Ascending Doses of JKN2501 for Injection in Chinese Healthy Volunteers · Phase 1 · recruiting
NCT07056881 — Monotherapy vs Combination Therapy for Bone Infections Caused by Pseudomonas Aeruginosa · recruiting
NCT06592586 — A Follow-up Trial of GBS-NN/NN2 Vaccine in Healthy Pregnant Women · Phase 2, PHASE3 · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06046937 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Victoriano Luna Medical Center
Last refreshed: 17 October 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06046937.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing